Price$14.72-0.12 (-0.78%)
01:30 PM07:45 PM
News · 26 weeks32+167%
2025-12-212026-06-14
Mix2090d
- Insider11(55%)
- SEC Filings5(25%)
- Other2(10%)
- Earnings2(10%)
Latest news
25 items- INSIDERChief Digital and Tech Officer Zecchini Edward J exercised 35,000 shares at a strike of $4.80 and sold $507,563 worth of shares (35,000 units at $14.50) (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- SECCryoPort Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Cryoport, Inc. (0001124524) (Filer)
- INSIDERDirector Baddour Linda was granted 10,350 shares, increasing direct ownership by 18% to 68,099 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERChief Financial Officer Stefanovich Robert sold $2,756,984 worth of shares (169,427 units at $16.27), decreasing direct ownership by 61% to 109,850 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERDirector Hancock Daniel M was granted 10,350 shares, increasing direct ownership by 18% to 69,052 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERDirector Hariri Robert J was granted 10,350 shares, increasing direct ownership by 20% to 61,625 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERDirector Mandalam Ramkumar was granted 10,350 shares and sold $358,452 worth of shares (23,214 units at $15.44), decreasing direct ownership by 16% to 67,894 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- SECSEC Form SD filed by CryoPort Inc.SD - Cryoport, Inc. (0001124524) (Filer)
- SECSEC Form 10-Q filed by CryoPort Inc.10-Q - Cryoport, Inc. (0001124524) (Filer)
- SECCryoPort Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cryoport, Inc. (0001124524) (Filer)
- PRCryoport Reports First Quarter 2026 Financial ResultsFirst quarter revenue grew 16% year-over-year to $47.8 millionCommercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programsLife Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices Life Sciences Products revenue increased 15% year-over-year, driven by strong demand for cryogenic systems Supporting a record 766 global clinical trials and 21 commercially approved CGTs as of March 31, 2026Company raises full-year revenue guidance to $192 million - $196 millionNASHVILLE, Tenn., May 4, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a le
- INSIDERPresident, CEO Shelton Jerrell exercised 104,007 shares at a strike of $1.87, increasing direct ownership by 9% to 1,230,614 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- SECSEC Form DEFA14A filed by CryoPort Inc.DEFA14A - Cryoport, Inc. (0001124524) (Filer)
- SECSEC Form DEF 14A filed by CryoPort Inc.DEF 14A - Cryoport, Inc. (0001124524) (Filer)
- PRCryoport to Report First Quarter 2026 Financial Results on May 4, 2026NASHVILLE, Tenn., April 20, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the first quarter ended March 31, 2026 on Monday, May 4, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2026 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued
- INSIDERSEC Form 4 filed by Shelton Jerrell4 - Cryoport, Inc. (0001124524) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
- INSIDERSEC Form 4 filed by Stefanovich Robert4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERSEC Form 4 filed by Shelton Jerrell4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERSEC Form 4 filed by Sawicki Mark W4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDEROfficer Zecchini Edward J was granted 21,322 shares and sold $16,112 worth of shares (2,014 units at $8.00), increasing direct ownership by 21% to 109,719 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERPresident, CEO Shelton Jerrell sold $63,344 worth of shares (7,918 units at $8.00), decreasing direct ownership by 0.75% to 1,054,501 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERChief Scientific Officer Sawicki Mark W was granted 22,845 shares and sold $25,880 worth of shares (3,235 units at $8.00), increasing direct ownership by 23% to 103,697 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERChief Financial Officer Stefanovich Robert exercised 87,188 shares at a strike of $1.87, sold $322,330 worth of shares (41,443 units at $7.78) and was granted 27,413 shares, increasing direct ownership by 35% to 280,371 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- SECSEC Form 144 filed by CryoPort Inc.144 - Cryoport, Inc. (0001124524) (Subject)
CYRX FAQ
6 questionsWhat does CryoPort Inc. do?
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities are...Where does CYRX stock trade?
CryoPort Inc. (CYRX) is listed on NASDAQ.What sector and industry is CYRX in?
CryoPort Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CYRX?
CryoPort Inc. has had 8 recent analyst actions on file. The most recent action was from KeyBanc Capital Markets: Overweight on 2025-08-06. Recent price targets range from $800.00 to $1600.00.What companies are similar to CYRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare CYRX side-by-side with any of them on Quantisnow.How can I track CYRX on Quantisnow?
Quantisnow aggregates CryoPort Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CYRX to receive live email and push alerts on every new disclosure.